Venous thromboembolism risk factors in pediatric patients with high-grade glioma: a multicenter retrospective study

BackgroundVenous Thromboembolism (VTE) is a significant complication in pediatric high-grade glioma (pHGG) patients, impacting prognosis and treatment outcomes. Identifying unique risk factors and pathophysiology in children is essential for targeted prevention and treatment.MethodsA multicenter ret...

Full description

Saved in:
Bibliographic Details
Main Authors: Yanxia Chen, Wenjing Fei, Yaqin Shi, Weiwei Ma, Wei Jiao, Fengqin Tao, Jie Zhu, Yuhai Wang, Xiaoyan Feng
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-08-01
Series:Frontiers in Pediatrics
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fped.2025.1595223/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849235882682351616
author Yanxia Chen
Wenjing Fei
Yaqin Shi
Weiwei Ma
Wei Jiao
Fengqin Tao
Jie Zhu
Yuhai Wang
Xiaoyan Feng
author_facet Yanxia Chen
Wenjing Fei
Yaqin Shi
Weiwei Ma
Wei Jiao
Fengqin Tao
Jie Zhu
Yuhai Wang
Xiaoyan Feng
author_sort Yanxia Chen
collection DOAJ
description BackgroundVenous Thromboembolism (VTE) is a significant complication in pediatric high-grade glioma (pHGG) patients, impacting prognosis and treatment outcomes. Identifying unique risk factors and pathophysiology in children is essential for targeted prevention and treatment.MethodsA multicenter retrospective analysis was conducted on pHGG patients enrolled between January 2012 and January 2024 at two hospitals. Data were collected from electronic medical records and follow-ups, focusing on VTE occurrence, clinical characteristics, and treatment outcomes. Statistical analyses included t-tests, Mann–Whitney U-tests, chi-square tests, and Cox regression models to identify risk factors and their impact on survival.ResultsOut of 216 screened patients, 168 met the inclusion criteria. The mean age was 9.87 ± 3.67 years, with 37.5% experiencing VTE. Tumor volume, grade, and specific genetic mutations significantly influenced VTE occurrence. Anticoagulation therapy, Isocitrate Dehydrogenase 1 (IDH1) mutations, O6-Methylguanine-DNA Methyltransferase (MGMT) methylation, radiotherapy, chemotherapy, and prolonged bed rest were protective against VTE, while increased tumor volume, Grade 4 glioma, Epidermal Growth Factor Receptor (EGFR) positivity, p53 mutations, glucocorticoid therapy and central venous catheter placement (CVCP) placement promoted VTE risk. The median survival time was 51.4 months, and VTE occurrence negatively impacted patient prognosis.ConclusionThis study highlights the risk factors for VTE in pHGG patients, emphasizing the need for tailored prevention and treatment strategies. The findings underscore the importance of clinical characteristics, genetic profiles, and treatment modalities in managing VTE and improving survival outcomes in pHGG.
format Article
id doaj-art-d3de2d68d6d147ca8d2140e3ff28aa5b
institution Kabale University
issn 2296-2360
language English
publishDate 2025-08-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Pediatrics
spelling doaj-art-d3de2d68d6d147ca8d2140e3ff28aa5b2025-08-20T04:02:32ZengFrontiers Media S.A.Frontiers in Pediatrics2296-23602025-08-011310.3389/fped.2025.15952231595223Venous thromboembolism risk factors in pediatric patients with high-grade glioma: a multicenter retrospective studyYanxia Chen0Wenjing Fei1Yaqin Shi2Weiwei Ma3Wei Jiao4Fengqin Tao5Jie Zhu6Yuhai Wang7Xiaoyan Feng8Department of Neurosurgery, The 904th Hospital of PLA, Medical School of Anhui Medical University, Wuxi, ChinaDepartment of Critical Care Medicine, Institute of General Surgery, PLA Eastern Theater Command General Hospital, Nanjing, ChinaDepartment of Neurosurgery, The 904th Hospital of PLA, Medical School of Anhui Medical University, Wuxi, ChinaDepartment of General Surgery, The 904th Hospital of PLA, Medical School of Anhui Medical University, Wuxi, ChinaDepartment of Nursing, The 904th Hospital of PLA, Medical School of Anhui Medical University, Wuxi, ChinaDepartment of Orthopedics, The 904th Hospital of PLA, Medical School of Anhui Medical University, Wuxi, ChinaDepartment of Nursing, The 904th Hospital of PLA, Medical School of Anhui Medical University, Wuxi, ChinaDepartment of Neurosurgery, The 904th Hospital of PLA, Medical School of Anhui Medical University, Wuxi, ChinaDepartment of Neurosurgery, The 904th Hospital of PLA, Medical School of Anhui Medical University, Wuxi, ChinaBackgroundVenous Thromboembolism (VTE) is a significant complication in pediatric high-grade glioma (pHGG) patients, impacting prognosis and treatment outcomes. Identifying unique risk factors and pathophysiology in children is essential for targeted prevention and treatment.MethodsA multicenter retrospective analysis was conducted on pHGG patients enrolled between January 2012 and January 2024 at two hospitals. Data were collected from electronic medical records and follow-ups, focusing on VTE occurrence, clinical characteristics, and treatment outcomes. Statistical analyses included t-tests, Mann–Whitney U-tests, chi-square tests, and Cox regression models to identify risk factors and their impact on survival.ResultsOut of 216 screened patients, 168 met the inclusion criteria. The mean age was 9.87 ± 3.67 years, with 37.5% experiencing VTE. Tumor volume, grade, and specific genetic mutations significantly influenced VTE occurrence. Anticoagulation therapy, Isocitrate Dehydrogenase 1 (IDH1) mutations, O6-Methylguanine-DNA Methyltransferase (MGMT) methylation, radiotherapy, chemotherapy, and prolonged bed rest were protective against VTE, while increased tumor volume, Grade 4 glioma, Epidermal Growth Factor Receptor (EGFR) positivity, p53 mutations, glucocorticoid therapy and central venous catheter placement (CVCP) placement promoted VTE risk. The median survival time was 51.4 months, and VTE occurrence negatively impacted patient prognosis.ConclusionThis study highlights the risk factors for VTE in pHGG patients, emphasizing the need for tailored prevention and treatment strategies. The findings underscore the importance of clinical characteristics, genetic profiles, and treatment modalities in managing VTE and improving survival outcomes in pHGG.https://www.frontiersin.org/articles/10.3389/fped.2025.1595223/fullpediatric high-grade gliomavenous thromboembolismrisk factorsanticoagulation therapysurvival outcomes
spellingShingle Yanxia Chen
Wenjing Fei
Yaqin Shi
Weiwei Ma
Wei Jiao
Fengqin Tao
Jie Zhu
Yuhai Wang
Xiaoyan Feng
Venous thromboembolism risk factors in pediatric patients with high-grade glioma: a multicenter retrospective study
Frontiers in Pediatrics
pediatric high-grade glioma
venous thromboembolism
risk factors
anticoagulation therapy
survival outcomes
title Venous thromboembolism risk factors in pediatric patients with high-grade glioma: a multicenter retrospective study
title_full Venous thromboembolism risk factors in pediatric patients with high-grade glioma: a multicenter retrospective study
title_fullStr Venous thromboembolism risk factors in pediatric patients with high-grade glioma: a multicenter retrospective study
title_full_unstemmed Venous thromboembolism risk factors in pediatric patients with high-grade glioma: a multicenter retrospective study
title_short Venous thromboembolism risk factors in pediatric patients with high-grade glioma: a multicenter retrospective study
title_sort venous thromboembolism risk factors in pediatric patients with high grade glioma a multicenter retrospective study
topic pediatric high-grade glioma
venous thromboembolism
risk factors
anticoagulation therapy
survival outcomes
url https://www.frontiersin.org/articles/10.3389/fped.2025.1595223/full
work_keys_str_mv AT yanxiachen venousthromboembolismriskfactorsinpediatricpatientswithhighgradegliomaamulticenterretrospectivestudy
AT wenjingfei venousthromboembolismriskfactorsinpediatricpatientswithhighgradegliomaamulticenterretrospectivestudy
AT yaqinshi venousthromboembolismriskfactorsinpediatricpatientswithhighgradegliomaamulticenterretrospectivestudy
AT weiweima venousthromboembolismriskfactorsinpediatricpatientswithhighgradegliomaamulticenterretrospectivestudy
AT weijiao venousthromboembolismriskfactorsinpediatricpatientswithhighgradegliomaamulticenterretrospectivestudy
AT fengqintao venousthromboembolismriskfactorsinpediatricpatientswithhighgradegliomaamulticenterretrospectivestudy
AT jiezhu venousthromboembolismriskfactorsinpediatricpatientswithhighgradegliomaamulticenterretrospectivestudy
AT yuhaiwang venousthromboembolismriskfactorsinpediatricpatientswithhighgradegliomaamulticenterretrospectivestudy
AT xiaoyanfeng venousthromboembolismriskfactorsinpediatricpatientswithhighgradegliomaamulticenterretrospectivestudy